| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1393051 | European Journal of Medicinal Chemistry | 2011 | 7 Pages |
Neuropathic pain is a chronic pain condition that occurs and persists in a heterogeneous group of etiologically different diseases characterized by a primary lesion or dysfunction of the peripheral or central nervous system. Current treatment options do not provide adequate relief for many patients and a significant number of the agents used have dose limiting side effects. During the course of our work on the synthesis and screening of new drugs for the treatment of neuropathic pain, we have identified 5-(4-nitrophenyl)furoic-2-acid hydrazones which showed significant antiallodynic and antihyperalgesic activities in a chronic constriction injury (CCI) model of neuropathic pain in rat. Synthesized compounds thus represent a promising lead for new drug development for the treatment of neuropathic pain.
Graphical abstractDuring the course of our work on the synthesis and screening of new drugs for the treatment of neuropathic pain, we have identified 5-(4-nitrophenyl) furoic-2-acid hydrazones which showed antiallodynic and antihyperalgesic activities.Figure optionsDownload full-size imageDownload as PowerPoint slideHighlights► Synthesis of newer leads for neuropathic pain. ► 5-(4-Nitrophenyl) furoic-2-acid hydrazones identified promising. ► Chronic constriction injury model in animals used to screen the compounds. ► Compounds more effective than carbamazepine and gabapentin.
